MAPP Map Pharmaceuticals, Inc. (MM)

CHICAGO, June 9 /PRNewswire/ -- In celebration of National Headache Awareness Week, the National Headache Foundation (NHF), with the support of MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), today debuted an educational video podcast for patients and physicians, titled "What's on the Horizon in Acute Headache Treatment?"

Click here to view the podcast.

"It's an exciting time to be a migraine clinician, as there are a wealth of promising options for both acute and preventative treatment in the pipeline," said Dr. Robert Kaniecki, Director of the Headache Center, Chief of Headache Division and Assistant Professor of Neurology at the University of Pittsburgh.

Dr. Kaniecki hosts the video podcast and shares important updates in the field of acute migraine research, including new ways of using proven drugs, new therapeutic targets and novel administration options.

This video podcast was sponsored by the NHF through an educational grant from MAP Pharmaceuticals, a company dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. Additional information about MAP Pharmaceuticals can be found at www.mappharma.com.

About Migraine

Common symptoms of migraine include recurrent headaches, nausea, vomiting, photophobia (sensitivity to light) and phonophobia (sensitivity to sound). According to the National Headache Foundation, most migraines last between four and 24 hours, and some last as long as three days. On average, migraine sufferers experience 1.5 migraine attacks monthly, although 25 percent of them experience one or more attacks weekly, according to published studies. Migraine patients report that currently approved drugs often do not fully meet their needs due to slow onset of action, short duration of effect, inconsistent response and unacceptable side effect profiles. The economic burden of migraine remains substantial despite existing treatments, with the direct and indirect costs of migraine in the United States estimated at over $20 billion annually.

About the National Headache Foundation

The National Headache Foundation, founded in 1970, is a non-profit organization which exists to enhance the healthcare of headache sufferers. It is a source of help to sufferers' families, physicians who treat headache sufferers, allied healthcare professionals and to the public. The NHF accomplishes its mission by providing educational and informational resources, supporting headache research and advocating for the understanding of headache as a legitimate neurobiological disease. For more information on headache causes and treatments, visit www.headaches.org or call 1-888-NHF-5552 (M-F, 9 a.m. to 5 p.m. CT).

SOURCE National Headache Foundation